Biotech Boom: Where are the Aussie Investors?

Biotech Boom: Where are the Aussie Investors?

Our managing Director, Dr Charlie Williams PhD, was interviewed by Nadine McGrath from Stockhead this month, talking about the why global biotech is increasingly an appealing investment proposition. Read the article in Stockhead Here: Global Biotech Sector set to Boom...
Macro has its hand on the tiller (again)

Macro has its hand on the tiller (again)

In May 2022 the biotechnology market was experiencing one if its greatest corrections since the index’s inception, having dropped 40% in 5 months.  Back then we were observing that the fundamentals of the Market had not changed, yet prices were depressed due to...
Why so many Aussie Biotechs Fail

Why so many Aussie Biotechs Fail

Our managing Director, Dr Charlie Williams PhD, was interviewed by Jared Lynch from The Australian this month, talking about the differences between the Australian and US Biotechnology sectors.  Read the article in The Australian Here: Why do so many Aussie Biotechs...
Prostate Cancer Radiotherapeutics

Prostate Cancer Radiotherapeutics

Australian investors have witnessed the rise of Telix Pharmaceuticals (ASX:TLX), which listed in 2017 with a market capitalisation of AU$128m and is now valued at AU$3.2 billion. The company’s PSMA-PET[i] diagnostic, Illucix, has garnered significant investor...
Sticking to your Guns

Sticking to your Guns

Looking back at FY23, one of the things that most stands out is that the level of outperformance achieved has reinforced the importance of Sticking to your Guns: Adherence to investment protocols. While considering what to focus on for this financial year end review,...